Site Map
Japanese
Business Unit
Pipeline
Social Responsibility
Corporate profile
Our Message
Corporate governance
Operation
Corporate history
List of offices
Business Unit
Ohara Pharmaceutical:Our mission
Orphan drugs (pharmaceuticals for rare medical conditions) business
Generic drugs business
Corporate profile
Our Message
Corporate governance
Operation
Corporate history
List of offices
News Release
トップ
>
English
>
News Release
>
Recombinant Chimeric Monoclonal Antibody “Dinutuximab (OP-08)”:Application Filed for Marketing Authorization for Neuroblastoma
Recombinant Chimeric Monoclonal Antibody “Dinutuximab (OP-08)”:Application Filed for Marketing Authorization for Neuroblastoma
September 24, 2020
Recombinant Chimeric Monoclonal Antibody "Dinutuximab (OP-08)":Application Filed for Marketing Authorization for Neuroblastoma
«
View List
»
